Alnylam Pharmace. buy JPMorgan Chase & Co.
Start price
13.10.25
/
50%
€406.80
Target price
13.10.26
€407.06
Performance (%)
-28.59%
Price
18:41
€290.50
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -28.59%. This prediction currently runs until 13.10.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.211% | -0.211% |
| iShares Core DAX® | 3.023% | 2.202% |
| iShares Nasdaq 100 | 3.561% | 1.325% |
| iShares Nikkei 225® | 6.618% | 5.707% |
| iShares S&P 500 | 2.635% | 1.008% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at JPMorgan Chase & Co. from $475.00 to $473.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€270.10
24.03.25
24.03.25
€302.97
24.03.26
24.03.26
-3.00%
25.03.26
25.03.26
